A study to check how safe, beneficial and tolerable the drug canakinumab is for patients with NOMID / CINCA syndrome

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001429-32

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This study will examine whether a medicine called canakinumab is safe and effective for treating patients with neonatal-onset multisystem inflammatory disease (NOMID), also known as chronic infantile neurologic, cutaneous, articular (CINCA) syndrome.


Critère d'inclusion

  • Neonatal onset multisystem inflammatory disease (abbreviated NOMID, also known as chronic infantile neurologic cutaneous and articular syndrome or CINCA)

Liens